Our previous work regarding bombesin agonist and bombesin antagonist-based NIRF imaging probes demonstrated the potential for delineating prostate tumors from normal tissues with high specificity and binding affinity in pre-clinical studies [32,33,36]. The gene discussed is GRP; the disease is prostate neoplasm.